Efficacia a lungo termine del trattamento di combinazione con encorafenib e binimetinib: caso clinico

Translated title of the contribution: Long-term efficacy of encorafenib plus binimetinib combined treatment: case report

Francesco Spagnolo

Research output: Contribution to journalArticlepeer-review

Abstract

Combination treatment with BRAF plus MEK inhibitors is a standard of care in patients with BRAF-mutant advanced melanoma. In addition to dabrafenib+trametinib and vemurafenib+cobimetinib, a new combination of BRAF and MEK inhibitors, encorafenib and binimetinib, was recently introduced into clinical practice. Encorafenib plus binimetinib achieved similar efficacy to that observed with previously available combinations, but incidence of some toxicities such as pyrexia and photosensitivity, which have a relevant impact on patients quality of life, is lower. In this article, the case of a patient who received encorafenib and binimetinib within the phase 3 trial COLUMBUS is presented and discussed, with a focus on the clinical management during the pandemic caused by SARS-CoV-2 virus.

Translated title of the contributionLong-term efficacy of encorafenib plus binimetinib combined treatment: case report
Original languageItalian
Pages (from-to)49e-52e
JournalRecenti Progressi in Medicina
Volume112
Issue number4
DOIs
Publication statusPublished - Apr 1 2021

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Long-term efficacy of encorafenib plus binimetinib combined treatment: case report'. Together they form a unique fingerprint.

Cite this